Alpelisib
Brand name: Piqray
Rank #466 of 500 drugs by total cost
$15.7M
Total Cost
747
Total Claims
$15.7M
Total Cost
54
Prescribers
$21K
Cost per Claim
0
Beneficiaries
757
30-Day Fills
$291K
Avg Cost/Provider
14
Avg Claims/Provider
About Alpelisib
Alpelisib (sold as Piqray) was prescribed 747 times by 54 Medicare Part D providers in 2023, costing the program $15.7M. At $21K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 463 | Leflunomide (Leflunomide) | $16.0M | 205,765 |
| 464 | Hydrocortisone (Hydrocortisone) | $15.9M | 762,398 |
| 465 | Digoxin (Digoxin) | $15.9M | 548,410 |
| 466 | Alpelisib (Piqray) | $15.7M | 747 |
| 467 | Doxazosin Mesylate (Doxazosin Mesylate) | $15.7M | 729,878 |
| 468 | Prucalopride Succinate (Motegrity) | $15.7M | 22,068 |
| 469 | Ketorolac Tromethamine (Ketorolac Tromethamine) | $15.6M | 582,750 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology